Trial Profile
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study of the Safety and Efficacy of CT 327, Pegylated K-252, Formulated as a Cream, When Administered Twice Daily for 14 Days to Subjects With Mild-to-Moderate Atopic Dermatitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2014
Price :
$35
*
At a glance
- Drugs Pegcantratinib (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Creabilis SA; Creabilis Therapeutics
- 17 Sep 2014 New trial record